pharma · Breast Cancer · Multiple Sclerosis (MS)
HOFFMANN-LA ROCHE
Hoffmann-La Roche
Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Mississauga, Ontario L5N 5M8, CA
- Employees
- 10
- Programs
- 286
- Drugs
- 212
- Patents
- 0
WO42633
Phase 3 · small molecule · Early human epidermal growth factor receptor 2 (HER2) positive breast cancer
WO42633 for Early human epidermal growth factor receptor 2 (HER2) positive breast cancer is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Internal code WO42633
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Early human epidermal growth factor receptor 2 (HER2) positive breast cancer
- Status
- active
- Trials
- 1